-
1 month ago | 
outsourcedpharma.com | Louis Garguilo
Contract manufacturing and packaging services that bring your vision to market.
Ropack is a leading provider of turnkey contract packaging and manufacturing services for the pharmaceutical and consumer healthcare industries. Flexible, agile and competitive, we deliver a full scope of services, all focused on reliably accelerating your go-to-market timeline.
-
1 month ago | 
outsourcedpharma.com | Louis Garguilo
A Revolutionary AI-Powered Inspection System for Pharmaceutical Manufacturing
Verista, a leading provider of automation, compliance, and quality solutions for the pharmaceutical industry, highlights the COUNTQ Tray Inspection System, an advanced AI-enabled inspection and reconciliation system designed to revolutionize the counting and verification of vials, syringes, ampoules, and other tray-loaded parts in pharmaceutical manufacturing.
-
1 month ago | 
outsourcedpharma.com | Louis Garguilo
Explore how shifting demand for oligos and peptides is driving outsourcing relationships and innovation in CDMO partnerships. Join our next Outsourced Pharma Live as we cover best practices for outsourcing these specialized therapeutics, focusing on capacity, regulatory challenges, and technology transfer. Register today to learn about the unique challenges and opportunities in scaling production for these complex molecules.
-
1 month ago | 
outsourcedpharma.com | Louis Garguilo
Upperton Pharma Solutions, a leading UK-based contract development and manufacturing organisation (CDMO), is proud to announce its selection as Champion Winner in the Small Molecule Dosage Form – International category at the 2025 CDMO Leadership Awards.
-
1 month ago | 
outsourcedpharma.com | Louis Garguilo
In the dynamic world of biologics manufacturing, change remains one of the few constants. As new modalities and innovations continuously emerge, the future holds promising prospects for patients. However, manufacturers face the challenge of keeping pace with these advancements and determining the best areas for investment. Amidst these changes, another significant trend is gaining serious momentum: sustainability.
-
1 month ago | 
outsourcedpharma.com | Louis Garguilo
Formulation and aseptic filling solutions are crucial for production needs ranging from early-stage clinical products to large-scale commercial products. Utilizing optimized processes for aseptic vial and syringe filling can increase manufacturing efficiency, minimize product loss, and ensure the required sterility for fill finish. Ajinomoto Bio-Pharma Services offers a unique range of formulation and aseptic filling in vials, prefilled syringes or cartridges.
-
1 month ago | 
outsourcedpharma.com | Louis Garguilo
Get more pharma outsourcing insight with our FREE newsletter
The HERMA 362C is a compact and flexible two-sided labeling machine designed for quick and easy changeovers. It operates largely without format parts, accommodating a wide range of product formats.
-
1 month ago | 
outsourcedpharma.com | Louis Garguilo
Get more pharma outsourcing insight with our FREE newsletter
Ropack Pharma Solutions utilizes state-of-the-art technology to ensure the efficacy, potency and robust shelf life of the products we manufacture and package.
HVAC Ventilation and AC Systems
Siemens controls
HEPA terminal filters
Positive pressure
Air return located 18 in.
-
1 month ago | 
outsourcedpharma.com | Louis Garguilo
Filtration is a ubiquitous process, integral to a myriad of applications ranging from simple preparative lab-scale tasks to stringent quality controls in large-scale Good Manufacturing Practice (GMP) production. Its versatility allows it to remove life-threatening contaminants, thereby safeguarding patient safety, or facilitating the smooth operation of other processes. Often, filtration is the go-to method for separating desired substances from undesired ones, typically based on size.
-
1 month ago | 
outsourcedpharma.com | Louis Garguilo
Guest Column
| March 21, 2025
A conversation with Judy Chou, Ph.D., AltruBio
On-site manufacturing for personalized therapies remains elusive for most companies. Infrastructure is lacking and, at a foundational level, there’s disagreement over how to solve the pressing challenge of logistics and accessibility for drugs that use patients’ own cells as starting materials.
